SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-23-000076
Filing Date
2023-08-02
Accepted
2023-08-02 16:07:10
Documents
62
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20230630.htm   iXBRL 10-Q 1372874
2 EX-31.1 allo-20230630xex311.htm EX-31.1 9786
3 EX-31.2 allo-20230630xex312.htm EX-31.2 9756
4 EX-32.1 allo-20230630xex321.htm EX-32.1 7013
  Complete submission text file 0001737287-23-000076.txt   6484609

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20230630.xsd EX-101.SCH 48371
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20230630_cal.xml EX-101.CAL 51624
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20230630_def.xml EX-101.DEF 256645
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20230630_lab.xml EX-101.LAB 630849
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20230630_pre.xml EX-101.PRE 387935
56 EXTRACTED XBRL INSTANCE DOCUMENT allo-20230630_htm.xml XML 767783
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 231135548
SIC: 2836 Biological Products, (No Diagnostic Substances)